Corstasis Therapeutics Unveils New Nasal Spray for Fluid Management in CHF and Kidney Disease at AHA 2024

New Nasal Spray Improves Management of Fluid Overload in Patients

Corstasis Therapeutics Inc. has announced the positive results of its pivotal trial for a new outpatient therapy, the bumetanide nasal spray (RSQ-777-02). This therapy aims to help patients with fluid overload due to congestive heart failure (CHF), liver, and kidney diseases. The findings will be presented at the American Heart Association’s annual Scientific Sessions in Chicago from November 16-18, 2024.

Benjamin Esque, CEO of Corstasis Therapeutics, stated that this presentation marks a significant achievement in providing easy-to-use outpatient solutions. The goal is to improve health equity by offering non-oral diuretic options, especially for patients in rural and underserved areas.

The presentation, titled “Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02),” will occur on November 18 from 8:30 to 8:40 AM CST. It will discuss the safety, efficacy, and pharmacokinetics of the nasal spray compared to traditional treatments.

About Bumetanide Nasal Spray (BNS)

Bumetanide Nasal Spray (BNS) is an investigational treatment designed for CHF, liver, and kidney disease patients. It allows patients to administer their own therapy easily at home, emphasizing convenience and independence.

About Corstasis Therapeutics Inc.

Corstasis Therapeutics develops therapies focused on improving the quality of life for patients with fluid overload issues. The company aims to optimize treatment outcomes, reduce hospital visits, and enhance access to vital therapies for diverse populations.

For more details, visit www.corstasis.com or connect with Corstasis on LinkedIn and X.